Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as nuzefatide pevedotin (BT5528)
nuzefatide pevedotin · 1 trial · 1 indication
Percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator
| Arm | Type | Description |
|---|---|---|
| nuzefatide pevedotin (BT5528) Monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| nuzefatide pevedotin (BT5528) | DRUG | Participants will receive nuzefatide pevedotin (BT5528) via intravenous (IV) infusion every 2 weeks (Q2W) |
Inclusion Criteria * At least 18 years of age at the time of signature of the informed consent form (or at least 19 years where locally defined as minimum age of consent). * Measurable disease as defined by RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Lif...
Nuzefatide pevedotin is an investigational small molecule being studied for the treatment of metastatic Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Nuzefatide pevedotin is a peptide-based small molecule, classified under the -tide (peptide) target class. Its specific molecular target has not been disclosed in available information.
Nuzefatide pevedotin is being developed by Bicycle Therapeutics plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol BCYC.
Nuzefatide pevedotin is currently in Phase 2 clinical trials. It is an investigational drug and has not received FDA approval for any indication.
Nuzefatide pevedotin is being evaluated in a Phase 2 clinical trial with the identifier NCT07450859. This study is recruiting patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the United States, with a planned enrollment of 39 participants.
Yes, nuzefatide pevedotin is also known as BT5528. Both names refer to the same investigational drug being developed by Bicycle Therapeutics for the treatment of metastatic Pancreatic Ductal Adenocarcinoma.